Aisling Capital Management LP Long-Term Concentrated

CIK: 0001766721 · Show all filings

Period: Q3 2024 (← Previous) (Next →)

Filing Date: Nov 13, 2024

Total Value ($000): $261,072 (100.0% shares, 0.0% debt)

Holdings (16)

BBIO BridgeBio Pharma Inc. (BBIO) 59.2%
Value ($000) $154,494 Shares 6,068,125 Est. Cost $40.43 Unrealized -35.1%
Verona Pharma plc (VRNA) 12.3%
Value ($000) $32,089 Shares 1,115,352 Est. Cost $7.38 Unrealized
SNDX Syndax Pharmaceuticals, Inc. (SNDX) 7.6%
Value ($000) $19,731 Shares 1,025,000 Est. Cost $10.24 Unrealized +101.8%
BCAX Bicara Therapeutics Inc. (BCAX) 5.6%
Value ($000) $14,490 Shares 568,919 Est. Cost $25.50 Unrealized 0.0%
BMEA Biomea Fusion Inc (BMEA) 3.1%
Value ($000) $8,067 Shares 798,757 Est. Cost $17.65 Unrealized -63.2%
GLUE Monte Rosa Therapeutics Inc (GLUE) 3.0%
Value ($000) $7,803 Shares 1,472,331 Est. Cost $20.37 Unrealized -75.2%
CMPS Compass Pathways Plc (CMPS) 2.3%
Value ($000) $6,076 Shares 964,500 Est. Cost $7.40 Unrealized
NUVB Nuvation Bio Inc. (NUVB) 2.2%
Value ($000) $5,819 Shares 2,541,009 Est. Cost $11.18 Unrealized -72.7%
Poseida Therapeutics Inc. (PSTX) 1.1%
Value ($000) $2,984 Shares 1,043,267 Est. Cost $8.87 Unrealized
TECX Tectonic Therapeutic Inc (TECX) 1.0%
Value ($000) $2,550 Shares 84,148 Est. Cost $15.77 Unrealized +15.9%
CALC CalciMedica, Inc. (CALC) 0.9%
Value ($000) $2,309 Shares 521,114 Est. Cost $4.55 Unrealized -3.4%
Elevation Oncology Inc (ELEV) 0.7%
Value ($000) $1,701 Shares 2,834,910 Est. Cost $13.57 Unrealized
Reneo Pharmaceuticals Inc (RPHM) 0.6%
Value ($000) $1,506 Shares 886,075 Est. Cost $9.33 Unrealized
MRKR Marker Therapeutics, Inc. (MRKR) 0.3%
Value ($000) $886 Shares 314,286 Est. Cost $1.74 Unrealized +127.6%
ACRS Aclaris Therapeutics Inc (ACRS) 0.2%
Value ($000) $500 Shares 434,455 Est. Cost $10.31 Unrealized -88.1%
Viracta Therapeutics Inc (VIRX) 0.0%
Value ($000) $66 Shares 288,571 Est. Cost $11.34 Unrealized